2021
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien A, Albain K, Kalinsky K, Wallace A, Elias A, Yee D, Clark A, Boughey J, Han H, Nanda R, Isaacs C, Mitri Z, Lang J, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo H, Hylton N, Symmans W, Melisko M, van't Veer L, Wilson A, Asare S, Sanil A, Berry D, Esserman L. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2021, 81: pd1-10-pd1-10. DOI: 10.1158/1538-7445.sabcs20-pd1-10.Peer-Reviewed Original ResearchStage II/III breast cancerWeekly x 4I-SPY 2 TRIALI-SPY 2PCR rateBreast cancerI-SPYPeripheral neuropathyHigh-risk stage II/III breast cancerTumor samplesRates of peripheral neuropathyControl armEvaluate novel agentsPathological complete responsePhase 2 trialTreatment of angiosarcomaModerate to high expressionSide effect profileTime of surgeryBayesian predictive probability of successBreast tumor samplesAntibody drug conjugatesHR-HER2Complete responseNeoadjuvant therapy
2020
Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
Li W, Onishi N, Newitt D, Gibbs J, Wilmes L, Jones E, Joe B, Sit L, Yau C, Chien A, Price E, Albain K, Kuritza T, Morley K, Boughey J, Brandt K, Choudhery S, Clark A, Rosen M, McDonald E, Elias A, Wolverton D, Fountain K, Euhus D, Han H, Niell B, Drukteinis J, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Asare S, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Berry D, DeMichele A, Abe H, Sheth D, Edmiston K, Ellis E, Ha R, Wynn R, Crane E, Dillis C, Nelson M, Church A, Isaacs C, Khan Q, Oh K, Jafarian N, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Sheth P, Hovanessian-Larsen L, Eghtedari M, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Goudreau S, Brown T, Esserman L, Hylton N. Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial. Cancer Research 2020, 80: pd9-04-pd9-04. DOI: 10.1158/1538-7445.sabcs19-pd9-04.Peer-Reviewed Original ResearchI-SPY 2 TRIALFunctional tumor volumeTumor volume progressionTumor progressionNon-pCRI-SPYTumor volumeHER2 subtypeVolume progressionCancer subtypesTumour progressorsEvaluate MRI changesI-SPY 2Triple negative subtypeHER2+ tumorsHigh-risk patientsNegative predictive valueBreast cancer subtypesEnhancement post-contrastTime pointsNumbers of patientsInsufficient image qualityTreatment time pointsPost-NACPre-NACAbstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
Li W, Onishi N, Newitt D, Harnish R, Jones E, Wilmes L, Gibbs J, Price E, Joe B, Chien A, Berry D, Boughey J, Albain K, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Yau C, Asare S, DeMichele A, Goudreau S, Abe H, Sheth D, Wolverton D, Fountain K, Ha R, Wynn R, Crane E, Dillis C, Kuritza T, Morley K, Nelson M, Church A, Niell B, Drukteinis J, Oh K, Jafarian N, Brandt K, Choudhery S, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Eghedari M, Sheth P, Hovanessian-Larsen L, Rosen M, McDonald E, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Esserman L, Hylton N. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI. Cancer Research 2020, 80: p6-02-01-p6-02-01. DOI: 10.1158/1538-7445.sabcs19-p6-02-01.Peer-Reviewed Original ResearchEffect of background parenchymal enhancementFunctional tumor volumeBackground parenchymal enhancementLower background parenchymal enhancementNeoadjuvant chemotherapyTumor volumeParenchymal enhancementDynamic contrast-enhancedHR-/HER2Treatment time pointsContralateral breastPatient cohortTime pointsHigher background parenchymal enhancementI-SPY 2 TRIALWeeks of neoadjuvant chemotherapyLocally advanced breast cancerMRI examsHormone receptorsHR-/HER2- subtypeMR tumor volumesPrediction of pCRNeoadjuvant chemotherapy regimensEnhancement thresholdHR-/HER2+Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
Onishi N, Li W, Newitt D, Harnish R, Gibbs J, Jones E, Nguyen A, Wilmes L, Joe B, Campbell M, Basu A, van’t Veer L, DiMichele A, Yee D, Berry D, Albain K, Boughey J, Chien A, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, Asare S, Yau J, Yau C, Esserman L, Hylton N. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer. Cancer Research 2020, 80: pd9-05-pd9-05. DOI: 10.1158/1538-7445.sabcs19-pd9-05.Peer-Reviewed Original ResearchPathological complete responseBackground parenchymal enhancementInferior treatment responseHormone receptor-positive breast cancerPathologic complete response rateReceptor-positive breast cancerPositive breast cancerTreatment responseHR cohortBreast cancerBreast MRINeoadjuvant chemotherapyNon-pCRDegree of BPEI-SPY 2 TRIALQuantitative background parenchymal enhancementStage II/III breast cancerContralateral breast parenchymaPost-NAC MRIHormone receptor statusHR+ breast cancerEffects of chemotherapyEnhanced suppressionStatistically significant associationHR+ cancersAbstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu M, Robinson P, Yau C, Wallace A, Chien A, Stringer-Reasor E, Nanda R, Yee D, Albain K, Boughey J, Han H, Elias A, Kalinsky K, Clark A, Kemmer K, Isaacs C, Lang J, Lu J, Sanft T, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Haugen P, Wilson A, Singhrao R, Asare S, Sanil A, Berry D, Esserman L. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2020, 80: p3-09-02-p3-09-02. DOI: 10.1158/1538-7445.sabcs19-p3-09-02.Peer-Reviewed Original ResearchPathological complete responseHER2 negative breast cancerI-SPY 2 TRIALWeeks of paclitaxelNegative breast cancerNeoadjuvant therapyBreast cancerHR-/HER2High-risk stage II/III breast cancerImmune-related adverse eventsPathologic complete response rateRandomized phase 2 trialStage II/III breast cancerHormone-receptorI-SPYEvaluate novel agentsGrade 3 colitisGrade 3 pneumonitisGrade 3 transaminitisPhase 2 trialPhase 3 trialBayesian predictive probability of successNeoadjuvant trialsWeekly paclitaxelComplete response